A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 526 participants.
Also called NCT04770532
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 526 participants
- Sponsor
- Registry
-
NCT04770532 -
2020-000454-10
-
- Main results
- Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Germany, Japan, Poland, Portugal, South Africa, South Korea, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04770532. Randomized; no masking; primary purpose treatment. Start 2021-03-05 (actual); primary completion 2022-01-27 (actual). Results posted on 2025-02-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- Acronym
- ONWARDS 2
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Insulin Icodec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04770532- Content hash
c60ee5b3cca47afc8b8d994efcf36fe09fbffa16f4f4f3213a64cffc6e53a4a9